BRIEF—CEO of regenerative medicine company resigns

Antony Odell is resigning from his role as chief executive of UK-based regenerative medicine company Tissue Regenix with immediate effect, the company has announced.

Mr Odell  spoke to The Pharma Letter only two months ago about his optimism that the company’s prospects after its  recent acquisition of CellRight Technologies, a USA-based specialist in regenerative osteoinductive bone scaffold.

Mr Odell had been in the role since 2008.

Despite his departure, the integration of CellRight is continuing as planned, a statement from the company said.